Orgenesis CEO Vered Caplan to Present at William Blair’s Biotech Focus Day Series: Cell and Gene Therapy Manufacturing
December 12 2018 - 01:47PM
Orgenesis Inc. (NASDAQ: ORGS), a developer of advanced cell
therapies, manufacturer and service provider today announced that
Vered Caplan, CEO of Orgenesis, will participate in William Blair’s
Biotech Focus Day Series: Cell and Gene Therapy Manufacturing,
which will combine experts and leading companies involved in the
rapid expansion of potentially curative therapies and the
logistical hurdles in their development.
Ms. Caplan will provide a morning presentation
entitled, “Thinking inside the box: centralized vs decentralized
manufacturing.” Ms. Caplan will also participate in a midday panel
discussion of current issues in manufacturing including scale up,
automation, release specifications, and commercial logistics.
The panel discussion will feature senior executives of leading
companies in the cell and gene therapy and manufacturing sectors,
including LogicBio Therapeutics, Rocket Pharmaceuticals, and
Celyad. The panel will be moderated by Philip Wills, Ph.D., Chief
Commercial Officer of Paragon Bioservices.
About OrgenesisOrgenesis is
vertically integrated service and research company in the
regenerative medicine industry with a focus on cell and gene
therapy development and manufacturing. The Company operates through
two platforms including (i) a Cell Therapy (“CT”) development
platform and (ii) a Contract Development and Manufacturing
Organization (“CDMO”) platform. Through the CT development
platform, Orgenesis is focused on the development of proprietary
cell therapies, including an autologous trans-differentiation
technology and therapeutic collaborations and licensing with other
pre-clinical and clinical-stage biopharma companies and research
and healthcare institutes. Through the CDMO platform, Orgenesis is
focused on manufacturing and development services for other
biopharma companies. The CDMO platform operates through Masthercell
Global, which currently consists of MaSTherCell in Belgium, Atvio
in Israel and subsidiaries in South Korea and in the United States,
each having unique know-how and expertise for manufacturing in a
multitude of cell types. These capabilities offered to
third-parties are also utilized for internal development projects,
with the goal of allowing Orgenesis to bring new products to
patients faster and in a cost-effective way. Additional information
is available at: www.orgenesis.com.
Notice Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements which are made pursuant to the safe harbor provisions of
Section 27A of the Securities Act of 1933, as amended and Section
21E of the Securities and Exchange Act of 1934, as amended.
These forward-looking statements involve substantial uncertainties
and risks and are based upon our current expectations, estimates
and projections and reflect our beliefs and assumptions based upon
information available to us at the date of this release. We
caution readers that forward-looking statements are predictions
based on our current expectations about future events. These
forward-looking statements are not guarantees of future performance
and are subject to risks, uncertainties and assumptions that are
difficult to predict. Our actual results, performance or
achievements could differ materially from those expressed or
implied by the forward-looking statements as a result of a number
of factors, including, but not limited to, the success of our
reorganized CDMO operations, the success of our partnership with
Great Point Partners, our ability to achieve and maintain overall
profitability, the sufficiency of working capital to realize our
business plans, the development of our transdifferentiation
technology as therapeutic treatment for diabetes which could, if
successful, be a cure for Type 1 Diabetes; our technology not
functioning as expected; our ability to retain key employees; our
ability to satisfy the rigorous regulatory requirements for new
procedures; our competitors developing better or cheaper
alternatives to our products and the risks and uncertainties
discussed under the heading "RISK FACTORS" in Item 1A of our Annual
Report on Form 10-K for the fiscal year ended November 30, 2017,
and in our other filings with the Securities and Exchange
Commission. We undertake no obligation to revise or update
any forward-looking statement for any reason.
Contact for Orgenesis:David
WaldmanCrescendo Communications, LLCTel:
212-671-1021Orgs@crescendo-ir.com
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Orgenesis (NASDAQ:ORGS)
Historical Stock Chart
From Mar 2023 to Mar 2024